The purpose of this study is to provide ongoing access to study treatments for participants
with multiple myeloma who are actively receiving daratumumab in a Janssen Research and
Development (R&D)-sponsored daratumumab study which has reached clinical cutoff for final
analysis and who continue to benefit from study treatment. Certain long-term safety data will
continue to be collected from study participants.